|
CN1926103B
(zh)
|
2004-03-11 |
2012-12-19 |
4Sc股份公司 |
磺酰基吡咯作为hdac抑制剂
|
|
WO2005115990A1
(ja)
|
2004-05-26 |
2005-12-08 |
Eisai R & D Management Co., Ltd. |
シンナミド化合物
|
|
US7781478B2
(en)
|
2004-07-14 |
2010-08-24 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
|
ES2338904T3
(es)
*
|
2004-10-26 |
2010-05-13 |
EISAI R&D MANAGEMENT CO., LTD. |
Forma amorfa de compuestos de cinamida.
|
|
WO2006076706A1
(en)
|
2005-01-14 |
2006-07-20 |
Millennium Pharmaceuticals, Inc. |
Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
|
|
SI1861365T1
(sl)
|
2005-03-15 |
2009-12-31 |
4Sc Ag |
N-sulfonilpiroli in njihova uporaba kot inhibitorji histon deacetilaze
|
|
CR9465A
(es)
*
|
2005-03-25 |
2008-06-19 |
Surface Logix Inc |
Compuestos mejorados farmacocineticamente
|
|
FR2886844B1
(fr)
*
|
2005-06-09 |
2007-09-14 |
Oreal |
Utilisation de composes 2-oxy-acetamide pour favoriser et/ou induire et/ou stimuler la pigmentation des matieres keratiniques et/ou limiter leur depigmentation et/ou leur blanchiment
|
|
EP1910297B1
(en)
|
2005-07-11 |
2016-05-25 |
Aerie Pharmaceuticals, Inc. |
Isoquinoline compounds
|
|
KR101256846B1
(ko)
|
2005-09-21 |
2013-04-24 |
4에스체 악티엔게젤샤프트 |
Hdac의 억제제로서의 신규한 설포닐피롤
|
|
JP5305909B2
(ja)
|
2005-09-21 |
2013-10-02 |
フォーエスシー アクチエンゲゼルシャフト |
ヒストンデアセチラーゼインヒビターとしてのスルホニルピロール塩酸塩
|
|
AU2006316005A1
(en)
*
|
2005-11-18 |
2007-05-24 |
Eisai R & D Management Co., Ltd. |
Process for production of cinnamamide derivative
|
|
WO2007058304A1
(ja)
*
|
2005-11-18 |
2007-05-24 |
Eisai R & D Management Co., Ltd. |
シンナミド化合物の塩またはそれらの溶媒和物
|
|
TWI370130B
(en)
|
2005-11-24 |
2012-08-11 |
Eisai R&D Man Co Ltd |
Two cyclic cinnamide compound
|
|
MY144960A
(en)
|
2005-11-24 |
2011-11-30 |
Eisai R&D Man Co Ltd |
Morpholine type cinnamide compound
|
|
HUE025173T2
(hu)
|
2005-12-13 |
2016-01-28 |
Incyte Corp |
Heteroaril-szubsztituált pirrollo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
|
|
US7989461B2
(en)
|
2005-12-23 |
2011-08-02 |
Amgen Inc. |
Substituted quinazolinamine compounds for the treatment of cancer
|
|
JP5583346B2
(ja)
*
|
2006-01-18 |
2014-09-03 |
エルジー ハウスホールド アンド ヘルスケア リミテッド |
c−Kit活性阻害剤、及び、肌美白剤
|
|
TWI378091B
(en)
|
2006-03-09 |
2012-12-01 |
Eisai R&D Man Co Ltd |
Multi-cyclic cinnamide derivatives
|
|
FI3719018T3
(fi)
|
2006-04-25 |
2025-10-07 |
Astex Therapeutics Ltd |
Puriini- ja deatsapuriinijohdannaisia farmaseuttisina yhdisteinä
|
|
EP2019094A4
(en)
*
|
2006-05-19 |
2011-01-05 |
Eisai R&D Man Co Ltd |
HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE
|
|
US7737141B2
(en)
|
2006-07-28 |
2010-06-15 |
Eisai R&D Management Co., Ltd. |
Prodrug of cinnamide compound
|
|
EP2526948A1
(en)
|
2006-09-20 |
2012-11-28 |
Aerie Pharmaceuticals, Inc. |
RHO kinase inhibitors
|
|
US8314119B2
(en)
|
2006-11-06 |
2012-11-20 |
Abbvie Inc. |
Azaadamantane derivatives and methods of use
|
|
US8455513B2
(en)
|
2007-01-10 |
2013-06-04 |
Aerie Pharmaceuticals, Inc. |
6-aminoisoquinoline compounds
|
|
TW200848054A
(en)
*
|
2007-02-28 |
2008-12-16 |
Eisai R&D Man Co Ltd |
Two cyclic oxomorpholine derivatives
|
|
US8263588B2
(en)
|
2007-04-06 |
2012-09-11 |
Neurocrine Biosciences, Inc. |
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
|
|
EP2155194B1
(en)
|
2007-04-06 |
2015-01-21 |
Neurocrine Biosciences, Inc. |
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
|
|
CN101679360A
(zh)
*
|
2007-05-16 |
2010-03-24 |
卫材R&D管理有限公司 |
一步生产肉桂酰胺衍生物的方法
|
|
EP3070090B1
(en)
|
2007-06-13 |
2018-12-12 |
Incyte Holdings Corporation |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
|
WO2009026276A1
(en)
|
2007-08-22 |
2009-02-26 |
Irm Llc |
5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
|
|
CA2694401C
(en)
|
2007-08-31 |
2012-12-04 |
Eisai R&D Management Co., Ltd. |
Polycyclic compound
|
|
US7935815B2
(en)
*
|
2007-08-31 |
2011-05-03 |
Eisai R&D Management Co., Ltd. |
Imidazoyl pyridine compounds and salts thereof
|
|
TWI453021B
(zh)
|
2007-10-11 |
2014-09-21 |
Astrazeneca Ab |
新穎蛋白質激酶b抑制劑
|
|
AU2008322426C1
(en)
|
2007-11-16 |
2014-10-23 |
Rigel Pharmaceuticals, Inc. |
Carboxamide, sulfonamide and amine compounds for metabolic disorders
|
|
ES2553340T3
(es)
|
2007-12-12 |
2015-12-07 |
Rigel Pharmaceuticals, Inc. |
Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
|
|
CA2706566A1
(en)
*
|
2007-12-18 |
2009-07-09 |
Glenmark Pharmaceuticals, S.A. |
Chromane derivatives as trpv3 modulators
|
|
US8455514B2
(en)
|
2008-01-17 |
2013-06-04 |
Aerie Pharmaceuticals, Inc. |
6-and 7-amino isoquinoline compounds and methods for making and using the same
|
|
CA2712095A1
(en)
*
|
2008-01-28 |
2009-08-06 |
Eisai R&D Management Co., Ltd. |
Crystalline cinnamide compounds or salts thereof
|
|
EA019488B1
(ru)
|
2008-04-21 |
2014-04-30 |
Лексикон Фармасьютикалз, Инк. |
Ингибиторы limk2 и способы их применения
|
|
CN104016980B
(zh)
|
2008-04-23 |
2016-12-07 |
里格尔药品股份有限公司 |
用于治疗代谢障碍的甲酰胺化合物
|
|
US8492568B2
(en)
|
2008-06-17 |
2013-07-23 |
Glenmark Pharamceuticals S.A. |
Chromane derivatives as TRPV3 modulators
|
|
US8450344B2
(en)
|
2008-07-25 |
2013-05-28 |
Aerie Pharmaceuticals, Inc. |
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
|
|
PT2384326E
(pt)
*
|
2008-08-20 |
2014-06-09 |
Zoetis Llc |
Compostos de pirrolo[2,3-d]pirimidina
|
|
WO2010052448A2
(en)
*
|
2008-11-05 |
2010-05-14 |
Ucb Pharma S.A. |
Fused pyrazine derivatives as kinase inhibitors
|
|
EP3053913B1
(en)
|
2009-05-01 |
2018-03-07 |
Aerie Pharmaceuticals, Inc. |
Dual mechanism inhibitors for the treatment of disease
|
|
LT2432472T
(lt)
|
2009-05-22 |
2020-02-10 |
Incyte Holdings Corporation |
3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai
|
|
TW201100429A
(en)
|
2009-05-22 |
2011-01-01 |
Incyte Corp |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
|
CN102574860A
(zh)
*
|
2009-10-15 |
2012-07-11 |
辉瑞大药厂 |
吡咯并[2,3-d]嘧啶化合物
|
|
JP5802677B2
(ja)
*
|
2009-12-01 |
2015-10-28 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
プロテインキナーゼc阻害剤およびその使用
|
|
US8198285B2
(en)
|
2010-01-19 |
2012-06-12 |
Astrazeneca Ab |
Pyrazine derivatives
|
|
CA2792508C
(en)
|
2010-03-10 |
2018-01-16 |
Incyte Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
TWI499421B
(zh)
|
2010-05-21 |
2015-09-11 |
Incyte Corp |
Jak抑制劑的局部製劑
|
|
CN106074548A
(zh)
|
2010-09-23 |
2016-11-09 |
艾伯维巴哈马有限公司 |
氮杂金刚烷衍生物的一水合物
|
|
AU2011329734B2
(en)
|
2010-11-19 |
2015-05-28 |
Incyte Holdings Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
|
JP5917544B2
(ja)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
|
|
MY169449A
(en)
|
2011-04-01 |
2019-04-11 |
Astrazeneca Ab |
Therapeutic treatment
|
|
ES2560611T3
(es)
|
2011-06-20 |
2016-02-22 |
Incyte Holdings Corporation |
Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
HRP20191982T4
(hr)
|
2011-11-30 |
2023-01-06 |
Astrazeneca Ab |
Kombinacijsko liječenje raka
|
|
JP6058023B2
(ja)
|
2011-12-15 |
2017-01-11 |
ファイザー・リミテッドPfizer Limited |
スルホンアミド誘導体
|
|
AU2013204533B2
(en)
|
2012-04-17 |
2017-02-02 |
Astrazeneca Ab |
Crystalline forms
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
US9181261B2
(en)
*
|
2012-05-22 |
2015-11-10 |
Merck Sharp & Dohme Corp. |
TrkA kinase inhibitors, compositions and methods thereof
|
|
SG10202111768XA
(en)
|
2012-11-15 |
2021-11-29 |
Incyte Holdings Corp |
Sustained-release dosage forms of ruxolitinib
|
|
US9828345B2
(en)
|
2013-02-28 |
2017-11-28 |
Bristol-Myers Squibb Company |
Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
|
|
TW201444798A
(zh)
|
2013-02-28 |
2014-12-01 |
必治妥美雅史谷比公司 |
作爲強效rock1及rock2抑制劑之苯基吡唑衍生物
|
|
PE20200298A1
(es)
|
2013-03-06 |
2020-02-06 |
Incyte Holdings Corp |
Procesos e intermedios para hacer un inhibidor de jak
|
|
CN105263494A
(zh)
|
2013-03-15 |
2016-01-20 |
爱瑞制药公司 |
联合治疗
|
|
CN114010611B
(zh)
|
2013-08-07 |
2023-11-28 |
因赛特控股公司 |
Jak1抑制剂的持续释放剂型
|
|
CN103910715B
(zh)
*
|
2014-03-26 |
2016-03-02 |
深圳翰宇药业股份有限公司 |
一种别嘌醇杂质c的合成方法
|
|
US9527812B2
(en)
|
2014-05-01 |
2016-12-27 |
Northwestern University |
N-heterocyclic carbene-catalyzed synthesis of 2-aryl indoles
|
|
WO2015170218A1
(en)
|
2014-05-07 |
2015-11-12 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
WO2016044463A2
(en)
|
2014-09-17 |
2016-03-24 |
Celgene Avilomics Research, Inc. |
Mk2 inhibitors and uses thereof
|
|
MY204050A
(en)
|
2015-10-21 |
2024-08-05 |
Otsuka Pharma Co Ltd |
Benzolactam compounds as protein kinase inhibitors
|
|
US9643927B1
(en)
|
2015-11-17 |
2017-05-09 |
Aerie Pharmaceuticals, Inc. |
Process for the preparation of kinase inhibitors and intermediates thereof
|
|
KR102579582B1
(ko)
|
2015-11-17 |
2023-09-15 |
에어리 파마슈티컬즈, 인코포레이티드 |
키나아제 억제제 및 이의 중간체의 제조 방법
|
|
EP3390387B1
(en)
|
2015-12-18 |
2021-11-17 |
Bayer Pharma Aktiengesellschaft |
Heteroarylbenzimidazole compounds
|
|
WO2017194453A1
(en)
*
|
2016-05-12 |
2017-11-16 |
Boehringer Ingelheim International Gmbh |
Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
|
|
WO2017207534A1
(en)
|
2016-06-03 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Substituted heteroarylbenzimidazole compounds
|
|
CN107663202B
(zh)
*
|
2016-07-29 |
2020-09-04 |
西华大学 |
3-(脲基-甲基)-4-芳基-吡啶衍生物及其制备方法和作为抗肝癌药物的应用
|
|
CN109640966A
(zh)
|
2016-08-31 |
2019-04-16 |
爱瑞制药公司 |
眼用组合物
|
|
WO2018045276A1
(en)
|
2016-09-02 |
2018-03-08 |
Ironwood Pharmaceuticals, Inc. |
Fused bicyclic sgc stimulators
|
|
WO2018165520A1
(en)
|
2017-03-10 |
2018-09-13 |
Vps-3, Inc. |
Metalloenzyme inhibitor compounds
|
|
CA3057872A1
(en)
|
2017-03-31 |
2018-10-04 |
Aerie Pharmaceuticals, Inc. |
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
|
|
GB201706327D0
(en)
|
2017-04-20 |
2017-06-07 |
Otsuka Pharma Co Ltd |
A pharmaceutical compound
|
|
JP2020518669A
(ja)
*
|
2017-05-03 |
2020-06-25 |
ビバーチェ セラピューティクス,インク. |
非縮合三環式化合物
|
|
TW201924683A
(zh)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
用於治療骨髓增生性贅瘤的低劑量組合療法
|
|
RS63312B1
(sr)
|
2018-01-30 |
2022-07-29 |
Incyte Corp |
Procesi za pripremu (1-(3-fluoro-2-(trifluorometil)izonikotinil)piperidin-4-on)
|
|
KR20200139153A
(ko)
|
2018-02-27 |
2020-12-11 |
인사이트 코포레이션 |
A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
|
|
MX2020010322A
(es)
|
2018-03-30 |
2022-11-30 |
Incyte Corp |
Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
|
|
JP7391046B2
(ja)
|
2018-05-18 |
2023-12-04 |
インサイト・コーポレイション |
A2a/a2b阻害剤としての縮合ピリミジン誘導体
|
|
CN117304191A
(zh)
|
2018-07-05 |
2023-12-29 |
因赛特公司 |
作为a2a/a2b抑制剂的稠合吡嗪衍生物
|
|
AU2019337703B2
(en)
|
2018-09-14 |
2023-02-02 |
Aerie Pharmaceuticals, Inc. |
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
CN112955215B
(zh)
|
2018-10-29 |
2024-05-17 |
勃林格殷格翰国际有限公司 |
吡啶基磺酰胺衍生物、药物组合物及其用途
|
|
CN112955214B
(zh)
|
2018-10-29 |
2024-05-07 |
勃林格殷格翰国际有限公司 |
吡啶基磺酰胺衍生物、药物组合物及其用途
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
|
CN114727974A
(zh)
|
2019-07-30 |
2022-07-08 |
艾科尼佐治疗股份有限公司 |
Hdac6抑制剂及其用途
|
|
CR20220066A
(es)
|
2019-08-14 |
2022-11-28 |
Incyte Corp |
Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
|
|
EP4021893A1
(en)
*
|
2019-08-29 |
2022-07-06 |
Hibercell, Inc. |
Perk inhibiting compounds
|
|
JOP20220087A1
(ar)
|
2019-10-11 |
2023-01-30 |
Incyte Corp |
أمينات ثنائية الحلقة كمثبطات لـ cdk2
|
|
CN117736207A
(zh)
|
2019-12-24 |
2024-03-22 |
卡尔那生物科学株式会社 |
二酰基甘油激酶调节化合物
|
|
AU2021219668B2
(en)
|
2020-02-14 |
2025-06-12 |
Gilead Sciences, Inc. |
Antibodies and fusion proteins that bind to CCR8 and uses thereof
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240025616A
(ko)
|
2021-06-23 |
2024-02-27 |
길리애드 사이언시즈, 인코포레이티드 |
다이아실글리세롤 키나제 조절 화합물
|
|
JP7654118B2
(ja)
|
2021-06-23 |
2025-03-31 |
ギリアード サイエンシーズ, インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
CN118139858A
(zh)
|
2021-10-28 |
2024-06-04 |
吉利德科学公司 |
吡地嗪-3(2h)-酮衍生物
|
|
WO2023077030A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
WO2023122615A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
EP4452414A2
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
|
ES2999273T3
(en)
|
2022-03-17 |
2025-02-25 |
Gilead Sciences Inc |
Ikaros zinc finger family degraders and uses thereof
|
|
KR20250004824A
(ko)
|
2022-04-21 |
2025-01-08 |
길리애드 사이언시즈, 인코포레이티드 |
Kras g12d 조절 화합물
|
|
IL317958A
(en)
|
2022-07-01 |
2025-02-01 |
Gilead Sciences Inc |
CD73 compounds
|
|
US20240254118A1
(en)
|
2022-12-22 |
2024-08-01 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
EP4695260A1
(en)
|
2023-04-11 |
2026-02-18 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20250175331A
(ko)
|
2023-04-21 |
2025-12-16 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|